Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Recruiting

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(3 sites)

China

Sun Yat-sen Memorial Hospital, Guangzhou

the First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Shantou Central Hospital, Shantou